BIO CEO & Investor Conference 2011
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that Dr. Gary S. Jacob, the company's president and chief executive officer, is scheduled to present at the 13th Annual BIO CEO and Investor Conference at 1:30 pm ET on February 14, 2011 at the Waldorf Astoria Hotel in New York City.
The live webcast may be accessed under the "Investor Relations" tab on the company's website at www.synergypharma.com. The webcast will be archived for 90 days.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. Plecanatide has recently completed a Phase IIa clinical trial in patients to treat CC. The Company plans to initiate a Phase II/III 90-day repeated-oral-dose, placebo-controlled clinical trial of plecanatide in CC patients in the second quarter of 2011. Plecanatide is also being developed to treat IBS-C, with the first trial in IBS-C patients planned for 2011. More information is available at http://www.synergypharma.com.